Operose Advisors LLC Has $26,000 Stake in CVS Health Co. (NYSE:CVS)

Operose Advisors LLC reduced its holdings in shares of CVS Health Co. (NYSE:CVS) by 76.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 590 shares of the pharmacy operator’s stock after selling 1,873 shares during the period. Operose Advisors LLC’s holdings in CVS Health were worth $26,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in the business. Morse Asset Management Inc bought a new stake in shares of CVS Health in the 3rd quarter valued at $409,000. Westside Investment Management Inc. grew its holdings in CVS Health by 4.6% in the third quarter. Westside Investment Management Inc. now owns 64,517 shares of the pharmacy operator’s stock worth $4,041,000 after purchasing an additional 2,856 shares during the period. World Investment Advisors LLC raised its holdings in shares of CVS Health by 280.7% during the third quarter. World Investment Advisors LLC now owns 27,543 shares of the pharmacy operator’s stock valued at $1,732,000 after purchasing an additional 20,308 shares during the period. Wilmington Savings Fund Society FSB bought a new position in shares of CVS Health during the 3rd quarter worth about $2,071,000. Finally, Tidal Investments LLC grew its stake in shares of CVS Health by 52.2% in the 3rd quarter. Tidal Investments LLC now owns 112,010 shares of the pharmacy operator’s stock valued at $7,043,000 after buying an additional 38,408 shares during the period. 80.66% of the stock is owned by institutional investors.

Insider Buying and Selling at CVS Health

In other CVS Health news, Director Michael F. Mahoney purchased 30,000 shares of the stock in a transaction dated Tuesday, February 18th. The shares were bought at an average price of $66.70 per share, with a total value of $2,001,000.00. Following the completion of the transaction, the director now directly owns 39,356 shares in the company, valued at approximately $2,625,045.20. This trade represents a 320.65 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP James David Clark sold 7,513 shares of CVS Health stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $66.35, for a total transaction of $498,487.55. Following the completion of the transaction, the senior vice president now owns 8,394 shares of the company’s stock, valued at $556,941.90. This represents a 47.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.24% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on CVS shares. Cantor Fitzgerald upgraded CVS Health from a “neutral” rating to an “overweight” rating in a report on Wednesday, February 12th. Evercore ISI lifted their price target on shares of CVS Health from $60.00 to $65.00 and gave the company an “outperform” rating in a research report on Monday, January 27th. JPMorgan Chase & Co. upped their price objective on shares of CVS Health from $80.00 to $81.00 and gave the stock an “overweight” rating in a report on Tuesday, February 18th. Argus set a $77.00 price objective on shares of CVS Health in a report on Tuesday, February 18th. Finally, Piper Sandler upped their target price on shares of CVS Health from $72.00 to $74.00 and gave the stock an “overweight” rating in a report on Friday, March 21st. Four equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $71.83.

CVS Health Stock Performance

NYSE CVS opened at $68.80 on Wednesday. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.60 and a current ratio of 0.81. The company has a market capitalization of $86.74 billion, a PE ratio of 18.80, a price-to-earnings-growth ratio of 0.98 and a beta of 0.57. CVS Health Co. has a 52-week low of $43.56 and a 52-week high of $71.66. The company has a 50-day simple moving average of $65.67 and a 200 day simple moving average of $58.63.

CVS Health (NYSE:CVS) last posted its quarterly earnings data on Wednesday, February 12th. The pharmacy operator reported $1.19 EPS for the quarter, beating the consensus estimate of $0.89 by $0.30. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. On average, research analysts predict that CVS Health Co. will post 5.89 EPS for the current year.

CVS Health Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, May 1st. Investors of record on Tuesday, April 22nd will be issued a $0.665 dividend. This represents a $2.66 annualized dividend and a yield of 3.87%. The ex-dividend date is Tuesday, April 22nd. CVS Health’s dividend payout ratio (DPR) is currently 72.68%.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.